Search Results - "ESTERNI, B"

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer by Gonçalves, A., Gilabert, M., François, E., Dahan, L., Perrier, H., Lamy, R., Re, D., Largillier, R., Gasmi, M., Tchiknavorian, X., Esterni, B., Genre, D., Moureau-Zabotto, L., Giovannini, M., Seitz, J-F., Delpero, J-R., Turrini, O., Viens, P., Raoul, J-L.

“…Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and angiogenic pathways. A phase I trial demonstrated that the combination of…”
Get full text

The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT by Devillier, R, Crocchiolo, R, Castagna, L, Fürst, S, El Cheikh, J, Faucher, C, Prebet, T, Etienne, A, Chabannon, C, Vey, N, Esterni, B, Blaise, D

“…We previously reported that reduced intensity conditioning (RIC) regimen with fludarabine, BU and 2.5 mg/kg of rabbit anti-thymocyte globulin (r-ATG) was…”
Get full text

Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study by Houvenaeghel, G., Goncalves, A., Classe, J.M., Garbay, J.R., Giard, S., Charytensky, H., Cohen, M., Belichard, C., Faure, C., Uzan, S., Hudry, D., Azuar, P., Villet, R., Gimbergues, P., Tunon de Lara, C., Martino, M., Lambaudie, E., Coutant, C., Dravet, F., Chauvet, M.P., Chéreau Ewald, E., Penault-Llorca, F., Esterni, B.

“…A subgroup of T1N0M0 breast cancer (BC) carries a high potential of relapse, and thus may require adjuvant systemic therapy (AST). Retrospective analysis of…”
Get full text

Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy by GONCALVES, A, ESTERNI, B, MENG, X.-Y, FUNG, E. T, BIRNBAUM, D, MARANINCHI, D, VIENS, P, BORG, J.-P, BERTUCCI, F, SAUVAN, R, CHABANNON, C, CUBIZOLLES, M, BARDOU, V. J, HOUVENAEGEL, G, JACQUEMIER, J, GRANJEAUD, S

“…A total of 30-50% of early breast cancer (EBC) patients considered as high risk using standard prognostic factors develop metastatic recurrence despite…”
Get full text

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer by Gravis, G., Bladou, F., Salem, N., Gonçalves, A., Esterni, B., Walz, J., Bagattini, S., Marcy, M., Brunelle, S., Viens, P.

“…Erlotinib is an orally active small-molecule tyrosine kinase inhibitor targeted against human epidermal growth factor receptor 1/epidermal growth factor…”
Get full text

Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs by Faucher, C, Le Corroller Soriano, A G, Esterni, B, Vey, N, Stoppa, A M, Chabannon, C, Mohty, M, Michallet, M, Bay, J O, Genre, D, Maraninchi, D, Viens, P, Moatti, J P, Blaise, D

“…We report the first randomized study comparing early hospital discharge with standard hospital-based follow-up after high-dose chemotherapy (HDCT) and PBSCT…”
Get full text

Critically ill cancer patients in the intensive care unit: short-term outcome and 1-year mortality by MOKART, D., ETIENNE, A., ESTERNI, B., BRUN, J.-P., CHOW-CHINE, L., SANNINI, A., FAUCHER, M., BLACHE, J.-L.

“…Background The short‐term survival of critically ill patients with cancer has improved over time. Studies providing long‐term outcome for these patients are…”
Get full text

Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT by Castagna, L, Fürst, S, Marchetti, N, El Cheikh, J, Faucher, C, Mohty, M, Bouabdallah, R, Vey, N, Stoppa, A M, Esterni, B, Blaise, D

“…In this retrospective study, 63 patients >60 years with hematological malignancies and treated with allo-SCT and with reduced-intensity conditioning (RIC) were…”
Get full text

Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer by LETESSIER, A, GARRIDO-URBANI, S, VIENS, P, CHARAFE -JAUFFRET, E, JACQUEMIER, J, BIRNBAUM, D, LOPEZ, M, CHAFFANET, M, GINESTIER, C, FOURNIER, G, ESTERNI, B, MONVILLE, F, ADELAÏDE, J, GENEIX, J, XERRI, L, DUBREUIL, P

“…Common fragile sites (CFSs) are regions of chromosomal break that may play a role in oncogenesis. The most frequent alteration occurs at FRA3B, within the FHIT…”
Get full text

A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis by Houvenaeghel, G, Nos, C, Giard, S, Mignotte, H, Esterni, B, Jacquemier, J, Buttarelli, M, Classe, J.-M, Cohen, M, Rouanet, P, Penault Llorca, F, Bonnier, P, Marchal, F, Garbay, J.-R, Fraisse, J, Martel, P, Fondrinier, E, Tunon de Lara, C, Rodier, J.-F

“…Abstract Purpose Predictive factors of non-sentinel lymph node (NSN) involvement at axillary lymph node dissection (ALND) have been studied in the case of…”
Get full text

Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors by Castagna, L, Crocchiolo, R, Furst, S, El-cheikh, J, Esterni, B, Granata, A, Stoppa, A, Boubdallah, R, Coso, D, Vey, N, Charbonnier, A, Lemarie, C, Faucher, C, Chabannon, C, Blaise, D

Get full text

Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors by Castagna, L, Crocchiolo, R, Furst, S, El-cheikh, J, Esterni, B, Granata, A, Stoppa, A, Boubdallah, R, Coso, D, Vey, N, Charbonnier, A, Lemarie, C, Faucher, C, Chabannon, C, Blaise, D

Get full text

Radiofrequency ablation associated to mucosal resection in the oesophagus: Experience in a single centre by Caillol, F, Bories, E, Pesenti, C, Poizat, F, Monges, G, Guiramand, J, Esterni, B, Giovannini, M

“…Abstract Endoscopic resection (EMR) and radiofrequency ablation (RFA) form part of the treatment of Barrett's oesophagus (BO), dysplasia, superficial…”
Get full text

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO) by Rousseau, F, Retornaz, F, Joly, F, Esterni, B, Abadie-Lacourtoisie, S, Fargeot, P, Luporsi, E, Servent, V, Laguerre, B, Brain, E, Geneve, J

“…Abstract Background Elderly metastatic cancer patients typically have short life expectancy and frequently suboptimal treatment. Goals of therapy should…”
Get full text

Equivalent survival in patients with advanced stage IB–II and III–IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy by Carcopino, X, Houvenaeghel, G, Buttarelli, M, Esterni, B, Tallet, A, Goncalves, A, Jacquemier, J

“…Abstract Objectives To evaluate survival in patients with advanced cervical cancer who underwent surgery after concurrent chemoradiotherapy. Methods One…”
Get full text

CD34 progenitors are reproducibly recovered in thawed umbilical grafts, and positively influence haematopoietic reconstitution after transplantation by LEMARIE, C, ESTERNI, B, CURTILLET, C, CHABANNON, C, MICHEL, G, CALMELS, B, DAZEY, B, LAPIERRE, V, LECCHI, L, MEYER, A, REA, D, THURET, I, CHAMBOST, H

“…Cord blood (CB) units are increasingly used for allogeneic transplantation. Cell dose, a major factor for CB selection, is evaluated before freezing by each CB…”
Get full text

105 Outcome of high risk myelodysplastic syndrome after azacytidine failure by Prebet, T, Gore, S.D, Esterni, B, Itzikson, R, Thepot, S, Beach, C.L, Fenaux, P, Vey, N

Get full text

Resection of residual masses after chemotherapy for advanced non-seminomatous germ cell tumours, a monocentric analysis of pre-operative prognosticators by DEVILLE, J.-L., GRAVIS, G., SALEM, N., SAVOIE, P.-H., ESTERNI, B., WALZ, J., THOMAS, P., GONCALVES, A., VIENS, P., BLADOU, F.

“…DEVILLE J.‐L., GRAVIS G., SALEM N., SAVOIE P.‐H., ESTERNI B., WALZ J., THOMAS P., GONCALVES A., VIENS P. & BLADOU F. (2010) European Journal of Cancer Care19,…”
Get full text

Predictive factors of tumour response after neoadjuvant chemoradiation for locally advanced rectal cancer and correlation of these factors with survival by Farnault, B, Moureau-Zabotto, L, de Chaisemartin, C, Esterni, B, Lelong, B, Viret, F, Giovannini, M, Monges, G, Delpero, J-R, Bories, E, Turrini, O, Viens, P, Resbeut, M

“…Neoadjuvant chemoradiation followed by surgery is the standard of care for locally advanced rectal cancer. The aim of this study was to correlate tumour…”
Get full text

O.9 Capecitabine (XELODA®, X) and oxaliplatine (ELOXATIN®, LOHP) regimen (XELOX) in elderly patients with metastatic colorectal cancer (MCRC): a FNCLCC French Collaborative Group GERICO 02 phase II study by Rousseau, F, Bugat, R, Ducreux, M, Cvitkovic, F, Carola, E, Gisselbrecht, M, Esterni, B, Gouttenoire, F, Viret, F

Get full text